ZA200803924B - Use of a CB1 antagonist for treating side effects and negative symtoms of schizophrenia - Google Patents

Use of a CB1 antagonist for treating side effects and negative symtoms of schizophrenia

Info

Publication number
ZA200803924B
ZA200803924B ZA200803924A ZA200803924A ZA200803924B ZA 200803924 B ZA200803924 B ZA 200803924B ZA 200803924 A ZA200803924 A ZA 200803924A ZA 200803924 A ZA200803924 A ZA 200803924A ZA 200803924 B ZA200803924 B ZA 200803924B
Authority
ZA
South Africa
Prior art keywords
symtoms
schizophrenia
antagonist
negative
side effects
Prior art date
Application number
ZA200803924A
Other languages
English (en)
Inventor
Black Mark
Borowsky Beth
Rogacki Nancy
Senyah Yaw
Stevens Rachel
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ZA200803924B publication Critical patent/ZA200803924B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200803924A 2005-12-08 2008-05-08 Use of a CB1 antagonist for treating side effects and negative symtoms of schizophrenia ZA200803924B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74843405P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
ZA200803924B true ZA200803924B (en) 2009-10-28

Family

ID=37964962

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200803924A ZA200803924B (en) 2005-12-08 2008-05-08 Use of a CB1 antagonist for treating side effects and negative symtoms of schizophrenia

Country Status (23)

Country Link
US (1) US20080221078A1 (fr)
EP (1) EP1962834A2 (fr)
JP (1) JP2009518423A (fr)
KR (1) KR20080073737A (fr)
CN (1) CN101321523A (fr)
AR (1) AR056846A1 (fr)
AU (1) AU2006321907A1 (fr)
BR (1) BRPI0619541A2 (fr)
CA (1) CA2632673A1 (fr)
CR (1) CR9957A (fr)
DO (1) DOP2006000273A (fr)
EC (1) ECSP088505A (fr)
IL (1) IL191888A0 (fr)
MA (1) MA30090B1 (fr)
NO (1) NO20082923L (fr)
PE (1) PE20071092A1 (fr)
RU (1) RU2008127491A (fr)
SV (1) SV2008002929A (fr)
TN (1) TNSN08205A1 (fr)
TW (1) TW200803839A (fr)
UY (1) UY29995A1 (fr)
WO (1) WO2007067617A2 (fr)
ZA (1) ZA200803924B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2009040659A2 (fr) 2007-09-28 2009-04-02 Purdue Pharma L.P. Composés benzènesulfonamides et leurs utilisations
JP2010540629A (ja) * 2007-10-04 2010-12-24 メルク・シャープ・エンド・ドーム・コーポレイション カルシウムチャネル遮断薬としての置換アリールスルホン誘導体
AR069700A1 (es) 2007-12-18 2010-02-10 Sanofi Aventis Derivados de azetidina,composiciones farmaceuticas que los comprenden, metodo de preparacion, intermediarios de sintesis,y usos de los mismos en el tratamiento o prevencion de trastornos psiquiatricos , del sistema inmune y gastrointestinales, entre otros.
FR2925051B1 (fr) * 2007-12-18 2010-05-21 Sanofi Aventis Derives d'azetidines,leur preparation et leur application en therapeutique
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
WO2010079241A1 (fr) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones
AU2015301891B2 (en) 2014-08-11 2019-12-05 Angion Biomedica Corporation Cytochrome P450 inhibitors and uses thereof
WO2016109492A1 (fr) 2014-12-31 2016-07-07 Angion Biomedica Corp Méthodes et agents pour traiter une maladie
CN109923102B (zh) 2016-08-24 2022-11-15 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗功能下降的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
BRPI0411131A (pt) * 2003-06-11 2006-07-18 Merck & Co Inc composto, método de tratar uma doença mediada pelo receptor de canabinóide 1, método de previnir a obesidade de uma pessoa com risco de obesidade, composição, e, uso de um composto
CA2537535A1 (fr) * 2003-09-02 2005-03-10 Solvay Pharmaceuticals Gmbh Nouvelles utilisations medicales d'antagonistes selectifs du recepteur cb<sb>1</sb>
WO2006017892A1 (fr) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Procedes d'amelioration du fonctionnement cognitif
FR2882931B1 (fr) * 2005-03-14 2007-05-18 Sanofi Aventis Sa Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique

Also Published As

Publication number Publication date
DOP2006000273A (es) 2007-10-15
JP2009518423A (ja) 2009-05-07
UY29995A1 (es) 2007-07-31
IL191888A0 (en) 2009-08-03
AR056846A1 (es) 2007-10-24
RU2008127491A (ru) 2010-01-20
WO2007067617A3 (fr) 2007-11-01
AU2006321907A1 (en) 2007-06-14
CR9957A (es) 2008-09-22
BRPI0619541A2 (pt) 2011-10-04
PE20071092A1 (es) 2007-12-10
MA30090B1 (fr) 2008-12-01
TW200803839A (en) 2008-01-16
CA2632673A1 (fr) 2007-06-14
KR20080073737A (ko) 2008-08-11
NO20082923L (no) 2008-09-02
WO2007067617A2 (fr) 2007-06-14
ECSP088505A (es) 2008-08-29
EP1962834A2 (fr) 2008-09-03
US20080221078A1 (en) 2008-09-11
TNSN08205A1 (en) 2009-10-30
SV2008002929A (es) 2009-12-02
CN101321523A (zh) 2008-12-10

Similar Documents

Publication Publication Date Title
ZA200803924B (en) Use of a CB1 antagonist for treating side effects and negative symtoms of schizophrenia
IL193014A0 (en) Methods and compositions for treating schizophrenia
SI2124999T1 (sl) Activin-actrii antagonisti in uporaba za zdravljenje anemije
EP2115570A4 (fr) Agents de protection et modes de privilège
EP1982627A4 (fr) Corps et outil de nettoyage
HK1208000A1 (en) Thioninium compounds and their use
EP2080470A4 (fr) Corps de nettoyage et outil de nettoyage
EP1982628A4 (fr) Corps et outil de nettoyage
PL1734959T3 (pl) Związki do leczenia schizofrenii i/lub nieprawidłowości w gospodarce glukozowej
EP2079313A4 (fr) Composés antimicrobiens et antiviraux et leurs procédés d&#39;utilisation
GB0611115D0 (en) Compounds and their use
IL192745A0 (en) Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
GB0712964D0 (en) Spray masks and line markers
IL199427A (en) Radiation-protective compounds and related methods
EP2069371A4 (fr) Composés d&#39;organo-arsénoxydes et leur utilisation
EP2027808A4 (fr) Corps de nettoyage et outl de nettoyage
EP2211841A4 (fr) Procédé de prophylaxie et agents destinés à être utilisés dans ce procédé
EP2068903A4 (fr) Composés de s-nitrosothiol, et dérivés associés
GB0619611D0 (en) Compounds and their use
ZA200905465B (en) Calcium reducing agents and methods
ZA200805398B (en) Use of kcnq-openers for treating or reducing the symptons of schizophrenia
GB0617317D0 (en) Iifa 2007 Yorkshire
AU2007905630A0 (en) A method of prophylaxis and agents for use therein
HK1172547A1 (en) Activin-actrii antagonists for use in treating anemia -actrii